EPIC-CAD - Edoxaban monotherapy vs. dual antithrombotic therapy for atrial fibrillation and stable coronary artery disease - report from ESC2024

Professor Gi-Byoung Nam explains thtat edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation and stable coronary artery disease, according to late-breaking research presented in a Hot Line session at ESC Congress 2024. Video: https://medicaldigest.org/scientific-contents/interview:epic-cad-edoxaban-monotherapy-vs-dual-antithrombotic-therapy-atrial-fibrillation-and-stable-coronary-artery-disease-report-esc2024